首页> 外文期刊>Stroke: A Journal of Cerebral Circulation >Local intraarterial fibrinolysis administered in aliquots for the treatment of central retinal artery occlusion: the Johns Hopkins Hospital experience.
【24h】

Local intraarterial fibrinolysis administered in aliquots for the treatment of central retinal artery occlusion: the Johns Hopkins Hospital experience.

机译:等分试样进行局部动脉内纤维蛋白溶解治疗,以治疗视网膜中央动脉阻塞:约翰霍普金斯医院的经验。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND AND PURPOSE: Central retinal artery occlusion results in acute visual loss with poor spontaneous recovery. Current standard therapies do not alter the natural history of disease. Several open-label clinical studies using continuous infusion of thrombolytic agents have suggested that local intraarterial fibrinolysis (LIF) is efficacious in the treatment of central retinal artery occlusion. The aim is to compare the visual outcome in patients with acute central retinal artery occlusion of presumed thromboembolic etiology treated with LIF administered in aliquots with that of patients treated with standard therapy. METHODS: We conducted a single-center, nonrandomized interventional study of consecutive patients with acute central retinal artery occlusion from July 1999 to July 2006. RESULTS: Twenty-one patients received LIF and 21 received standard therapy. Seventy-six percent of subjects in the LIF group had a visual acuity improvement of one line or more compared with 33% in the standard therapy group (P=0.012, Fisher exact). Multivariate logistic regression controlling for gender, history of prior stroke/transient ischemic attack, and history of hypercholesterolemia showed that patients who received tissue plasminogen activator were 36 times more likely to have improvement in visual acuity (P=0.0001) after adjusting for these covariates. Post hoc analysis showed that patients who received tissue plasminogen activator were 13 times more likely to have improvement in visual acuity of 3 lines or more (P=0.03) and 4.9 times more likely to have a final visual acuity of 20/200 or better (P=0.04). Two groin hematomas were documented in the LIF group. No ischemic strokes, retinal or intracerebral hemorrhages were documented. CONCLUSIONS: LIF administered in aliquots is associated with an improvement in visual acuity compared with standard therapy and has few side effects.
机译:背景与目的:视网膜中央动脉阻塞导致急性视力丧失,自发恢复能力差。当前的标准疗法不会改变疾病的自然史。一些使用连续输注血栓溶解剂的开放标签临床研究表明,局部动脉内纤维蛋白溶解(LIF)在治疗视网膜中央动脉阻塞方面有效。目的是将等分给予LIF治疗的假定的血栓栓塞病因与急性视网膜中央动脉闭塞的患者的视觉结果与标准治疗的患者进行比较。方法:我们从1999年7月至2006年7月对连续的急性视网膜中央动脉阻塞患者进行了单中心,非随机干预研究。结果:21例患者接受LIF治疗,21例接受标准治疗。与标准治疗组的33%相比,LIF组的76%的受试者的视敏度提高了1行或更多(P = 0.012,Fisher精确)。通过多因素逻辑回归分析,控制性别,既往中风/短暂性脑缺血发作史和高胆固醇血症史,接受组织纤溶酶原激活剂的患者在调整这些协变量后,视力改善的可能性提高了36倍(P = 0.0001)。事后分析显示,接受组织纤溶酶原激活剂的患者,其3线或以上视力改善的可能性高13倍(P = 0.03),其最终视力20/200或更高的可能性高4.9倍( P = 0.04)。 LIF组有两个腹股沟血肿。没有缺血性中风,视网膜或脑出血的记录。结论:与标准疗法相比,以等份方式服用LIF可使视力得到改善,且副作用很少。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号